Relevant bibliographies by topics / Primary brain tumor

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers

Academic literature on the topic 'Primary brain tumor'

Author: Grafiati
Published: 4 June 2021
Last updated: 8 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Primary brain tumor.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Primary brain tumor"

1

&NA;. "Responding to primary brain tumor." Nursing 37, no. 1 (January 2007): 43. http://dx.doi.org/10.1097/00152193-200701000-00035.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Tamura, Ryota, Yoshiaki Kuroshima, and Yoshiki Nakamura. "Primary Neuroendocrine Tumor in Brain." Case Reports in Neurological Medicine 2014 (2014): 1–6. http://dx.doi.org/10.1155/2014/295253.

Full text
Abstract:
The incidence of brain metastases for neuroendocrine tumor (NET) is reportedly 1.5~5%, and the origin is usually pulmonary. A 77-year-old man presented to our hospital with headache and disturbance of specific skilled motor activities. Computed tomography (CT) showed a massive neoplastic lesion originating in the left temporal and parietal lobes that caused a mass edematous effect. Grossly, total resection of the tumor was achieved. Histological examination revealed much nuclear atypia and mitotic figures. Staining for CD56, chromogranin A, and synaptophysin was positive, indicating NET. The MIB-1 index was 37%. Histopathologically, the tumor was diagnosed as NET. After surgery, gastroscopy and colonoscopy were performed, but the origin was not seen. After discharge, CT and FDG-PET (fluoro-2-deoxy-d-glucose positron emission tomography) were performed every 3 months. Two years later we have not determined the origin of the tumor. It is possible that the brain is the primary site of this NET. To our knowledge, this is the first reported case of this phenomenon.
APA, Harvard, Vancouver, ISO, and other styles
3

Gilbert, Mark R. "Primary brain tumors, delta 24 and tumor metabolism." Expert Review of Neurotherapeutics 13, no. 4 (April 2013): 353–55. http://dx.doi.org/10.1586/ern.13.28.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Tunjungsari, Dyah, DjumhanaAtmakusuma, Freddy Sitorus, Joedo Prihartono, Teguh A. S. Ranakusuma, Salim Harris, Astri Budikayanti, and Tiara Aninditha. "Coagulation Profile Comparison Between Primary Brain Tumor and Secondary Brain Tumor." Advanced Science Letters 24, no. 9 (September 1, 2018): 6437–41. http://dx.doi.org/10.1166/asl.2018.12739.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Stone, Jacqueline B., Joanne F. Kelvin, and Lisa M. DeAngelis. "Fertility preservation in primary brain tumor patients." Neuro-Oncology Practice 4, no. 1 (December 9, 2016): 40–45. http://dx.doi.org/10.1093/nop/npw005.

Full text
Abstract:
Abstract Background Fertility preservation (FP) is an infrequently addressed issue for young adults with primary brain tumors. Given the improved prognosis and enhanced technology in reproductive medicine, more primary brain tumor patients see procreation as feasible, making the discussion of FP increasingly important. The goals of this study were to describe patients who received FP counseling by a fertility nurse specialist (FNS) and determine which sociodemographic and disease-related factors predict acceptance of referral to a reproductive specialist. Methods Institutional review board-approved retrospective review of primary brain tumor patients, ages 18 to 45, who were referred for FP counseling with a FNS from 2009 to 2013. Results Seventy patients were referred for FP counseling: 38 men, 32 women, with a median age of 32 years and median KPS of 90. Eighty-nine percent had gliomas; 58% grade III, 17% grade IV. Sixty-seven percent were referred for counseling at initial diagnosis. Of those referred, 73% accepted referral to a sperm bank (87% of men) or reproductive endocrinologist (56% of women). Patients were more likely to accept referral if they had no prior children (P = .048). There was no statistically significant difference in referral acceptance by age, race/ethnicity, marital status, religion, or tumor grade. After treatment, 3 men conceived naturally, 2 men conceived using banked sperm, and 2 women conceived naturally. Conclusions Despite the historically poor prognosis of patients with primary brain tumors, there is significant interest in FP among these patients, particularly if they have no prior children. Clinicians should develop strategies to incorporate FP counseling into practice.
APA, Harvard, Vancouver, ISO, and other styles
6

Balachandran, Akilandeswari A., Leon M. Larcher, Suxiang Chen, and Rakesh N. Veedu. "Therapeutically Significant MicroRNAs in Primary and Metastatic Brain Malignancies." Cancers 12, no. 9 (September 7, 2020): 2534. http://dx.doi.org/10.3390/cancers12092534.

Full text
Abstract:
Brain cancer is one among the rare cancers with high mortality rate that affects both children and adults. The most aggressive form of primary brain tumor is glioblastoma. Secondary brain tumors most commonly metastasize from primary cancers of lung, breast, or melanoma. The five-year survival of primary and secondary brain tumors is 34% and 2.4%, respectively. Owing to poor prognosis, tumor heterogeneity, increased tumor relapse, and resistance to therapies, brain cancers have high mortality and poor survival rates compared to other cancers. Early diagnosis, effective targeted treatments, and improved prognosis have the potential to increase the survival rate of patients with primary and secondary brain malignancies. MicroRNAs (miRNAs) are short noncoding RNAs of approximately 18–22 nucleotides that play a significant role in the regulation of multiple genes. With growing interest in the development of miRNA-based therapeutics, it is crucial to understand the differential role of these miRNAs in the given cancer scenario. This review focuses on the differential expression of ten miRNAs (miR-145, miR-31, miR-451, miR-19a, miR-143, miR-125b, miR-328, miR-210, miR-146a, and miR-126) in glioblastoma and brain metastasis. These miRNAs are highly dysregulated in both primary and metastatic brain tumors, which necessitates a better understanding of their role in these cancers. In the context of the tumor microenvironment and the expression of different genes, these miRNAs possess both oncogenic and/or tumor-suppressive roles within the same cancer.
APA, Harvard, Vancouver, ISO, and other styles
7

Aulia Hanum, Achmad Bayhaqi Nasir Aslam, Yuyun Yueniwati, Diah Prabawati Retnani, and Nanik Setjowati. "Measurement of the peritumoral edema and tumor volume ratio in differentiating malignant primary and metastatic brain tumor." GSC Biological and Pharmaceutical Sciences 13, no. 2 (November 30, 2020): 055–61. http://dx.doi.org/10.30574/gscbps.2020.13.2.0295.

Full text
Abstract:
Malignant primary and metastatic brain tumors are group of malignancies radiologically difficult to distinguish between one another. Meanwhile, the treatment regimens between the two entities are very different. The right regimen can maintain patient’s survival. MRI is the modality of choice for diagnosing brain tumors; although, malignant primary brain tumors and solitary metastases appear similar on conventional MRI. The difference in the pathophysiology of peritumoral edema in malignant primary and metastatic brain tumors has the potential for differentiation of the two entities. In malignant primary brain tumors, tumor cell infiltration occurs in the edema area, meaning that the peritumoral edema is narrower than that of the metastases. This study analyzed the ratio of peritumoral edema volume to tumor (EP/T volume ratio) in malignant primary and metastatic brain tumors by means of MRI examination with a cross-sectional design, using MRI data on FLAIR and T1WI sequences with contrast in malignant brain tumor of patients that have been pathologically proven. Then, volume contouring was performed on peritumoral edema (EP) and tumor (T), and comparation was done to obtain the EP/T volume ratio. The ratio of EP/T volume data in both groups was analyzed using the Mann–Whitney test with the SPSS 22 software. The results of statistical analysis revealed that the EP/T volume ratio of the malignant primary brain tumor group was smaller with a median value (max-min) of 1.1 (5.65-0.17) and in the metastatic group, 2.3 (64.03-0.09). There was a significant difference in the EP/T volume ratio between the two groups, which the brain metastatic tumor group have a double ratio of EP/T with a value of p=0.008 (p<0.05).
APA, Harvard, Vancouver, ISO, and other styles
8

Kijima, Noriyuki, Yoshikazu Nakajima, Daisuke Kanematsu, Tomoko Shofuda, Yuichiro Higuchi, Hiroshi Suemizu, Kanji Mori, et al. "TMOD-29. ESTABLISHMENT OF PATIENT-DERIVED XENOGRAFTS FROM RARE PRIMARY BRAIN TUMORS." Neuro-Oncology 22, Supplement_2 (November 2020): ii234. http://dx.doi.org/10.1093/neuonc/noaa215.979.

Full text
Abstract:
Abstract Patient derived xenografts are essential tools for translational research and preclinical development of novel therapeutic strategies of primary brain tumors. Recent advances in genomics of primary brain tumors revealed molecular classification of primary brain tumors, thus establishment of patient derived xenografts from each subtype of primary brain tumors is urgently needed. However, currently available patient derived xenografts are limited and are from specific subtype of primary brain tumors such as glioblastoma IDH wild type. In this study, we aim to establish patient derived xenografts from primary brain tumors with various molecular characteristics, especially rare primary brain tumors. We got primary brain tumor tissues from patients, dissociated those tissue into single cells, and orthotopically injected those cells into NOD/Shi-scid IL2Rγ KO mouse. We successfully established rare patient-derived xenografts from atypical teratoid rhabdoid tumor and CNS Ewing sarcoma family tumor with CIC alteration, which is recently described as new entity of primitive neuroectodermal tumors of the CNS. We also analyzed histopathological characteristics of these xenografts and found that each xenograft well recapitulated histopathological features of original patients’ resected tumors. These xenografts have advantages for translational research and preclinical development of novel therapeutic strategies for rare primary brain tumors. In addition, further efforts are needed to establish other types of rare primary brain tumors.
APA, Harvard, Vancouver, ISO, and other styles
9

LIANG, RUICHAO, and FANG FANG. "THE APPLICATION OF NANOMATERIALS IN DIAGNOSIS AND TREATMENT FOR MALIGNANT PRIMARY BRAIN TUMORS." Nano 09, no. 01 (January 2014): 1430001. http://dx.doi.org/10.1142/s1793292014300011.

Full text
Abstract:
Malignant primary brain tumors have a very high morbidity and mortality. Even though enormous advances have been made in primary brain tumor management, in the case of malignant primary brain tumors, current diagnostic strategies cannot identify exact infiltrating margins, surgery alone cannot achieve total mass resection, and adjuvant therapies cannot improve survivals. Therefore, there is an urgent need to explore novel strategies to diagnose and treat such infiltrating brain tumors. Nanomaterials, particularly zero-dimensional and one-dimensional platforms, can carry various compounds such as contrast agents, anticancer drugs and genes into brain tumor cells specifically. Thus, contrast agent-based nanomaterials can selectively present infiltrating tumor outlines, while anticancer agent-based nanomaterials can specifically kill malignant tumor cells. In addition, dual-targeting nanomaterials, multifunctional nanocarriers, theranostic nanovehicles as well as convection-enhanced delivery technology hold promise to increase drug accumulation in tumor tissues, which could largely improve anticancer efficacy. In this review, we will mainly focus on the application of nanomaterials in preoperative diagnosis, intraoperative diagnosis and adjuvant treatment for malignant primary brain tumors.
APA, Harvard, Vancouver, ISO, and other styles
10

Wiffen, Philip J. "MULTIDISCIPLINARY REHABILITATION AFTER PRIMARY BRAIN TUMOR TREATMENT." Journal of Pain & Palliative Care Pharmacotherapy 27, no. 2 (June 2013): 180. http://dx.doi.org/10.3109/15360288.2013.810898.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Primary brain tumor"

1

Richards, Homa Lisa Ann. "Perceptions of Caregivers Following Diagnosis of Primary Benign Brain Tumor." ScholarWorks, 2019. https://scholarworks.waldenu.edu/dissertations/7422.

Full text
Abstract:
A brain tumor diagnosis is traumatic and has a devastating impact upon the caregiver and the family unit. The effects of the tumor growth and treatment often cause significant neurologic injury and dramatically affect the quality of life (QOL) for the patient and their entire family unit. Caregivers are constantly challenged to provide care, yet they feel untrained and underprepared as they struggle to adjust to new roles and responsibilities. The purpose of this study is to gain an understanding of the lived experiences of caregivers of individuals with primary benign brain tumor (PBBT). An interpretive phenomenological analysis approach was used to explore the experiences of 10 caregivers. Bowen's family systems theory provided an understanding of how families respond to changes in their family system resulting from a member of the family having a PBBT. A nonprobability sampling technique was used to recruit participants from 2 virtual support groups. Data were collected through semistructured interviews guided by an interview template. Interviews were transcribed and analyzed following the Smith tradition of inquiry until data saturation was reached. Three major themes emerged from the data: experiencing new challenges, responding to initial diagnosis, and facing challenges with family and friends. Caregivers experience a wide variety of responsibilities that are physically and psychologically challenging, which can negatively affect the QOL for the caregiver and the patient. These findings can be used by healthcare providers to identify resources to alleviate the unanticipated demands caregivers experience. Future studies are needed to explore how best to decrease challenges experienced by caregivers of individuals with PBBT.
APA, Harvard, Vancouver, ISO, and other styles
2

Linendoll, Nadine M. "Family caregivers' perceived symptom distress of persons with a primary malignant brain tumor." Thesis, Boston College, 2008. http://hdl.handle.net/2345/38.

Full text
Abstract:
Thesis advisor: Ellen Mahoney
The diagnosis of a primary malignant brain tumor (PMBT) can be devastating for individuals and their families due to the limited treatment options and poor prognosis. Patients often rely on family members to manage their care; however, many caregivers feel under-prepared and overwhelmed by the experience. Though caring for a person with a PMBT is challenging and complex, little research has addressed the family caregiver's performance. The purpose of this study was to identify the extent to which preparedness and caregiver role strain explained the family caregiver’s performance in symptom management. An adapted theoretical framework, The Theory of Unpleasant Symptoms for Family Caregivers, guided this study. The study employed a descriptive, correlational research design in which the researcher obtained cross-sectional data during one collection period. The participants were adults who identified themselves as family caregivers of persons with a PMBT. Forty caregivers were enrolled in the study at the Brain Tumor Center at Beth Israel Deaconess Medical Center. Results from the regression analyses indicated that caregiver role strain and preparedness explained 31% of the variance (adjusted R2) in perceived psychological symptom distress and 29% (adjusted R2) of the variance in perceived physical symptom distress. Caregiver role strain was the major contributor to psychological (B=.68, p=.000) and physical symptoms (B=.48, p=0.001), indicating that higher levels of caregiver role strain were predictive of higher levels of perceived symptom distress and this relationship was strong. Preparedness contributed less to the explained variance in psychological (B=-.24, p=.20) and physical symptoms (B=-.21, p=.14). The negative beta indicates that higher preparedness was related to lower perceived symptom distress, but this relationship was small when compared with role strain. This study informs clinicians in neuro-oncology that care giver role strain is often high in family caregivers of patients with a PMBT and can have a negative impact on caregiver performance. These findings also support the need for more tailored nursing interventions to assist caregivers with ways to decrease caregiver role strain and improve caregiver preparedness
Thesis (PhD) — Boston College, 2008
Submitted to: Boston College. Connell School of Nursing
Discipline: Nursing
APA, Harvard, Vancouver, ISO, and other styles
3

Krug, Jeffrey Bart Litofsky N. Scott Chandrasekhar Anand. "Functional outcome and self-perceived overall health status following surgery to remove primary brain tumor." Diss., Columbia, Mo. : University of Missouri--Columbia, 2008. http://hdl.handle.net/10355/5754.

Full text
Abstract:
The entire thesis text is included in the research.pdf file; the official abstract appears in the short.pdf file; a non-technical public abstract appears in the public.pdf file. Title from PDF of title page (University of Missouri--Columbia, viewed on September 25, 2009). Thesis advisors: Dr. N. Scott Litofsky & Dr. Anand Chandrasekhar. Includes bibliographical references.
APA, Harvard, Vancouver, ISO, and other styles
4

Chowath, Rashmi. "Role of Aurora kinase in Medulloblastoma development with correlation to MYCN activity." Thesis, Uppsala universitet, Institutionen för biologisk grundutbildning, 2015. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-255237.

Full text
Abstract:
Brain tumors are abnormal tissue masses found, either malignant or benign in nature. Medulloblastoma is a brain tumor subtype found to arise in the hind region of the brain, which is highly malignant and has poor long term prospects in general. On the basis of the driving force behind the tumor, medulloblastoma is further subgrouped into 4 categories: WNT; SHH; Group 3 and Group 4 tumors. Group 3 tumors show a high expression of N-Myc protein which is seen in certain types of cancerous cells. The cell cycle is regulated at several checkpoints by cyclin/cdk inhibitors. The primary cilium is an organelle found on the cellular surface, which has functions in cell growth, differentiation and neurogenesis. Aurora kinase is a protein kinase involved in the regulation and maintainence of the cilium. Often the cilium gets deleted from the cellular surface in tumors coupled with an increase in the kinase level inside the cells. Hence aurora kinase is found to be a viable target for therapy. Aurora kinase is also involved in stabilizing the MYCN gene by protecting it from degradation. In this project, the primary cilum was studied in neural stem cells and followed by study of its presence on tumor cells in culture. The gene involved in cilium development i.e. Kif3a was mutated and its aggressive nature was compared with that of the tumor cells. Aurora kinase was commonly found to be over-expressed in both the tumors and the mutants whereas N-Myc over-expression was seen only in tumors. Experiments suggest that cilia repression in Kif3a mutants takes place via an aurora kinase dependent pathway.
APA, Harvard, Vancouver, ISO, and other styles
5

Pawl, Jean. "Sleep Loss and its Health Impact Among Family Caregivers of Persons with a Primary Malignant Brain Tumor." Digital Archive @ GSU, 2011. http://digitalarchive.gsu.edu/nursing_diss/25.

Full text
Abstract:
Sleep impairments for caregivers are multifactorial. Assumptions are that caregivers of those with primary malignant brain tumors (PMBT) are similar to caregivers of persons with dementia as cognitive impairments are present at diagnosis. The shorter trajectory of PMBTs and rapid deterioration of recipients’ health may influence sleep in caregivers of persons with a PMBT. The purposes of this study were to use a sleep impairment model to characterize caregiver sleep using objective and subjective measures, and to examine sleep loss effects on psychosocial and physiologic health outcomes. A secondary data analysis using baseline data from a larger study of mind-body interactions in caregivers of family members with PMBTs was used. Caregiver data included standardized questionnaires, serum blood draw, and three-day sleep-wake activity data from an accelerometer. Analyses included descriptive statistics, correlations, t-tests, and hierarchical regression models. Caregivers (N = 133) were White (94%), female (69.2%) spouses (75.2) and on average 52 years old (SD = 11.8). Care recipients were mainly White males of similar age with a highly malignant glioma (57.4%). Sleep latency was longer (35 min, SD = 34.5), with shorter total sleep time (TST) (357 min, SD = 84.6) and more frequent wake after sleep onset (WASO; 15.1%, SD = 9.2) than in the general population. Caregivers reported high anxiety (59.4%). Caregiver comorbidities and care recipient functioning explained higher perceptions of health (R2 = 26, F(2, 84) = 14.94, p < .001). Whereas, longer TST, more WASO and poorer sleep quality explained poorer quality of life (R2 = .27, F(4, 66) = 6.19, p < .001). Sleep loss variables explained little variance in physical health status, interleukin-1ra and interleukin-6 levels, fatigue, depressive symptoms, spiritual health, social support, and work limitations. Nurses need to assist caregivers with anxiety management and ways to improve sleep at time of PMBT diagnosis. Sleep impairments place these caregivers at risk for physical and mental health problems, and compromise their ability to continue in the role.
APA, Harvard, Vancouver, ISO, and other styles
6

Mainio, A. (Arja). "Depressive and anxious symptomatology in relation to a primary brain tumor:prospective study of neurosurgical patients in Northern Finland." Doctoral thesis, University of Oulu, 2005. http://urn.fi/urn:isbn:9514277163.

Full text
Abstract:
Abstract The findings on depression and anxiety among brain tumor patients have so far been based on case series and case samples. In Finland, psychiatric research in relation to psychiatric symptoms among patients with different types of brain tumors is lacking. The study population of this thesis consisted of 101 patients (39 males and 62 females) aged between 20 and 82 years with a solitary primary brain tumor treated surgically at the Oulu Clinic for Neurosurgery, Oulu University Hospital between February 1990 and March 1992. The major histological subgroup consisted of gliomas (40%), and the rest were meningiomas (33%), acoustic neurinomas (13%), pituitary adenomas (8%) and other types (6%). The psychiatric symptoms of the patients were assessed at three time points, namely before tumor operation as well as at three months and at one year after operation by two valid measurement instruments, the Beck Depression Inventory and the Crown Crisp Experiential Index. In addition, the patients' functional state was evaluated by the Karnofsky Performance Scale and their quality of life according to Sintonen 15 D. Prevalence of at least mild depression before tumor operation was 30% for males and 38% for females. The mean depressive scores decreased significantly for up to one-year during follow-up for both males and females, but they remained notably high in all patients. Decreased functional status (KPS under 70) in the patients was significantly associated with high depressive scores at all measurement points. The decrease in the mean depressive scores was significant among patients with an anterior tumor and those with a pituitary adenoma. Five-year survival of the brain tumor patients was found to be mainly associated with the histology of the tumor. Survival time in months (SD) of the patients with high-grade (III–IV) gliomas was shown to be 22.5 (21.4), while it was 50.2 (19.9) for the patients with low-grade (I–II) gliomas, and 58.2 (9.4) for the rest of the patients. Depression among low-grade glioma patients was significantly associated with worse survival at five years follow-up. The level of anxiety was shown to be significantly higher among patients with a primary brain tumor in the right hemisphere compared to the anxiety scores among patients with left hemispheric tumors. A significant increase was found in the level of obsessionality over time in the female patients with a brain tumor in the left anterior location of the brain at three months after operation. The level of quality of life (QOL) was significantly worse among female brain tumor patients compared to males. Depressive females had significantly lower quality of life compared to that of non-depressive females up to one-year follow-up after surgical operation of the tumor. Depression, anxiety and obsessive-compulsive symptoms have to be recognized and be treated by psychotherapy and pharmacotherapy as soon as possible at every unit where brain tumor patients are followed and encountered.
APA, Harvard, Vancouver, ISO, and other styles
7

Beccaria, Kévin. "Evaluation de la diffusion intracérébrale des drogues antinéoplasiques après ouverture de la barrière hémato-encéphalique induite par ultrasons : Application aux gliomes malins de l’enfant Brainstem Blood-Brain Barrier Disruption and Enhanced Drug Delivery with an Unfocused Ultrasound Device – A Preclinical Study in Healthy and Tumor-Bearing Mice Ultrasound-Induced Blood-Brain Barrier Disruption for the Treatment of Gliomas and other Primary CNS Tumors Blood-Brain Barrier Disruption with Low-Intensity Pulsed Ultrasound for the Treatment of Pediatric Brain Tumors: A Review and Perspectives." Thesis, université Paris-Saclay, 2020. http://www.theses.fr/2020UPASS044.

Full text
Abstract:
Les gliomes de haut grade représentent près de 15% de l’ensemble des tumeurs cérébrales de l’enfant. Aucun progrès thérapeutique n’a été fait depuis 30 ans et leur pronostic reste effroyable. La barrière hémato-encéphalique (BHE) est l’une des causes de l’échec des traitements médicaux car elle limite le passage de la majorité des molécules vers le cerveau, empêchant la plupart des drogues antinéoplasiques d’atteindre le tissu tumoral. L’ouverture de la BHE par les ultrasons pulsés de faible intensité en association avec des microbulles injectées par voie intraveineuse est une technique qui permet d’ouvrir transitoirement la BHE de manière localisée et sécurisée. Dans cette étude, nous avons confirmé la capacité d’un nouvel agent de contraste (microbulles) à ouvrir la BHE avec des ultrasons. Nous avons par ailleurs montré qu’il était possible d’ouvrir la BHE dans le tronc cérébral avec un dispositif ultrasonore non focalisé (SonoCloud®), à la fois sur des souris saines et des modèles murins de DIPG. Nous avons pu augmenter la distribution de l’irinotécan et du panobinostat dans le tronc cérébral de souris saines et de modèles de DIPG après ouverture de la BHE, sans cependant améliorer la survie de notre modèle de DIPG. Des études préliminaires ont été réalisées avec des inhibiteurs de chekpoints et des cellules natural killer, qui n’ont pas permis d’améliorer la survie d’un modèle murin de gliome malin sus-tentoriel. Enfin, nous avons mis au point le premier essai clinique pédiatrique qui visera, dès le premier semestre 2020, à évaluer la faisabilité et la tolérance de l’ouverture de la BHE avec le dispositif SonoCloud® chez l’enfant et l’adolescent
High-grade gliomas represent about 15% of pediatric brain tumors. No progress has been made in the treatment of these tumors during the last decades, and their prognosis remains dismal. The blood-brain barrier (BBB) plays a major role in the failure of medical treatments since it prevents most molecules to reach the brain, thus limiting the delivery of antineoplastic drugs to brain tumors. Disruption of the BBB (BBBD) with low intensity pulsed ultrasound in association with intravenous microbubbles is a technique that allows for safe, transient, and localized opening of the BBB. In this thesis, we confirmed the capacity of a new microbubble contrast agent to induce BBBD with ultrasound. We showed that opening of the BBB in the brainstem is possible with a nonfocused ultrasound device (SonoCloud®), in both healthy mice and a murine model of DIPG. We were able to increase irinotecan and panobinostat delivery in the brainstem of both healthy and tumor-bearing mice after BBBD, but we did not observe increased in overall survival. Preliminary studies have also been performed with checkpoints inhibitors and natural killer cells in a murine model of supra-tentorial high-grade glioma, but we were not able to increase survival in these models anymore. Finally, we prepared the first clinical trial that will evaluate the feasibility and tolerance of ultrasound-induced BBBD with the SonoCloud® device in the pediatric population. This trial will begin during the first semester of 2020
APA, Harvard, Vancouver, ISO, and other styles
8

Sung, Ching-Ching. "Gangliosides in human primary brain tumors /." The Ohio State University, 1995. http://rave.ohiolink.edu/etdc/view?acc_num=osu1487864986609959.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Meisen, Walter Hans. "Improving Oncolytic Viral Therapy for Primary and Metastatic Tumors in the Brain." The Ohio State University, 2015. http://rave.ohiolink.edu/etdc/view?acc_num=osu1429187113.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Wilczynska, Katarzyna Marta. "Inflammation-associated gene regulation in primary astrocytes, glial tumors and cellular differentiation." VCU Scholars Compass, 2008. http://hdl.handle.net/10156/1772.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Primary brain tumor"

1

Virginia. General Assembly. Joint Legislative Audit & Review Commission. Evaluation of House Bill 2156: mandated coverage of second opinions for primary malignant brain tumor patients at NCI Comprehensive Cancer Center. Richmond, Va: Commonwealth of Virginia, 2007.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Fields, William S., ed. Primary Brain Tumors. New York, NY: Springer New York, 1989. http://dx.doi.org/10.1007/978-1-4612-3676-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Primary central nervous system tumors: Pathogenesis and therapy. New York: Humana Press, 2011.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Ibegbu, Chinazom, and Nimish A. Mohile. Brain Tumors in Pregnancy. Edited by Emma Ciafaloni, Cheryl Bushnell, and Loralei L. Thornburg. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780190667351.003.0018.

Full text
Abstract:
Approximately 79,000 people are diagnosed with a central nervous system (CNS) tumor each year, but only a few of these patients are pregnant women. There is no evidence that pregnancy confers an increased risk of developing a brain tumor and incidence during child-bearing years is estimated to be 12.24 per 100,000 women. The care and management of all patients with primary brain tumors can be challenging and requires a multidisciplinary team that includes neurologists, medical neuro-oncologists, neurosurgeons, radiation-oncologists, and palliative care physicians. In a pregnant patient, this multidisciplinary team should also include a high-risk obstetrician. This chapter provides a detailed care map for pregnant patients with brain tumors. All management decisions regarding the neoplasm must consider the health of the expectant mother, the health of the fetus, the neurological and medical complications due to the brain tumor, and the potential effect that the brain tumor has on the patient’s survival.
APA, Harvard, Vancouver, ISO, and other styles
5

Theeler, Brett J., and Mark R. Gilbert. Primary Central Nervous System Tumors. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199937837.003.0129.

Full text
Abstract:
Ependymomas are rare primary central nervous system (CNS) tumors that are thought to arise from ependymal cells lining the ventricular system located throughout the CNS. Ependymomas occur in all age groups but are more common in the pediatric population. Ependymomas typically present as mass lesions within the ventricular system, brain or spinal cord parenchyma. As with most central nervous system tumors, pathologic evaluation is required for definitive diagnosis. Ependymomas are typically treated with a combination of surgery and radiotherapy although this varies depending on tumor location, tumor grade, patient age, extent of tumor resection, and other pretreatment factors. Recent molecular studies demonstrate molecularly defined tumor heterogeneity that appears to have a region-specific pattern. Translating the emerging molecular profiles of ependymomas into improved treatment strategies is the primary goal of ongoing research efforts.
APA, Harvard, Vancouver, ISO, and other styles
6

Eseonu, Chikezie I., Jordina Rincon-Torroella, and Alfredo Quiñones-Hinojosa. Unusual Gliomas. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780190696696.003.0002.

Full text
Abstract:
Patients with intra-axial brain tumors often present with neurologic symptoms based on the anatomic location of their tumor. Workup for a brain tumor includes cranial imaging such as magnetic resonance imaging and computed tomography, as well as systemic imaging to assess for primary tumor if metastasis is suspected. Maximal safe resection optimizes outcomes including overall survival. Surgical decisions are based on variables such as medical comorbidities and anatomic location of the tumor. Gliomas in eloquent areas may require intraoperative cortical and subcortical mapping of motor and/or language areas to optimize safety and help maximize resection. Adjuvant chemotherapy and radiation lead to a median survival of 14.6 months for patients with glioblastoma. Rapidly recurring glioblastoma after surgery has a poor prognosis.
APA, Harvard, Vancouver, ISO, and other styles
7

Kaley, Thomas J. Oligodendrogliomas. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199937837.003.0128.

Full text
Abstract:
Gliomas represent the most common symptomatic primary brain tumors, of which oligodendrogliomas are the least common subtype of glioma.1 The traditional thinking is that although the rarest, they also offer patients the best prognosis and they are deemed to be the most sensitive to treatment. However, although they may have a longer average survival than most other gliomas, nearly all patients with an oligodendroglioma will ultimately succumb to their illness due to either progressive and recurrent tumor or malignant transformation into a higher grade tumor. Optimal treatment of oligodendroglial tumors, especially those harboring a 1P/19Q codeletion, remains controversial.
APA, Harvard, Vancouver, ISO, and other styles
8

Huntoon, Kristin, and J. Bradley Elder. High-Grade Gliomas. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780190696696.003.0001.

Full text
Abstract:
Glioblastoma is the most common primary malignant brain tumor. This chapter discusses the clinical presentation and initial workup for a patient with a suspected glioblastoma, as well as the optimal treatment strategy and prognosis. Diagnosis is typically made using magnetic resonance imaging. Optimal treatment involves maximal safe surgical resection followed by adjuvant chemotherapy and radiation therapy. Surgical adjuncts including intraoperative imaging modalities and brain mapping techniques help improve neurologic morbidity associated with surgery. Despite maximal treatment, virtually all patients with glioblastoma will experience recurrence of their tumor and may be considered for clinical trials or second-line therapy. This chapter highlights important pearls associated with management of patients with glioblastoma and written for those who are interested in neuro-oncology, neurosurgery, and the field of brain tumors.
APA, Harvard, Vancouver, ISO, and other styles
9

Primary Brain Tumors. Springer My Copy UK, 1989.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Primary Brain Tumors. Springer Verlag, 1989.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Primary brain tumor"

1

Preston-Martin, Susan, Faith Davis, and Roberta McKean-Cowdin. "Epidemiology of Primary Brain Tumors." In Brain Tumor Immunotherapy, 47–71. Totowa, NJ: Humana Press, 2001. http://dx.doi.org/10.1007/978-1-59259-035-3_2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Duff, John M., Pierre-Yves Dietrich, and Nicolas de Tribolet. "Current Therapy for Primary Brain Tumors." In Brain Tumor Immunotherapy, 73–87. Totowa, NJ: Humana Press, 2001. http://dx.doi.org/10.1007/978-1-59259-035-3_3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Sugawa, Noriaki, Yoshio Nakagawa, and Satoshi Ueda. "Point Mutations of Epidermal Growth Factor Receptor Transcripts in Primary Human Malignant Gliomas." In Brain Tumor, 233–36. Tokyo: Springer Japan, 1996. http://dx.doi.org/10.1007/978-4-431-66887-9_23.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Rorke, Lucy Balian. "Primitive Neuroectodermal Tumor - A Concept Requiring an Apologia?" In Primary Brain Tumors, 5–15. New York, NY: Springer New York, 1989. http://dx.doi.org/10.1007/978-1-4612-3676-4_2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Mischel, Paul S., and Harry V. Vinters. "Neuropathology and Molecular Pathogenesis of Primary Brain Tumors." In Brain Tumor Immunotherapy, 3–45. Totowa, NJ: Humana Press, 2001. http://dx.doi.org/10.1007/978-1-59259-035-3_1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Wechsler, Wolfgang, and Guido Reifenberger. "Application of Immunohistochemistry for Tumor Grading in Human Neuro-Oncology." In Primary Brain Tumors, 133–42. New York, NY: Springer New York, 1989. http://dx.doi.org/10.1007/978-1-4612-3676-4_10.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Mandonnet, Emmanuel, and Hugues Duffau. "Mapping the Brain for Primary Brain Tumor Surgery." In Malignant Brain Tumors, 63–79. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-49864-5_5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Schorb, E., and C. F. Waller. "The Value of Anti-angiogenics in Primary Brain Tumor Therapy." In Tumor Angiogenesis, 1–18. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-31215-6_29-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Schorb, E., and C. F. Waller. "The Value of Anti-angiogenics in Primary Brain Tumor Therapy." In Tumor Angiogenesis, 609–25. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-319-33673-2_29.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Oleaga, Laura, Javier Moreno, Mariano Werner, and Nuria Bargalló. "Primary Intra-Axial Brain Tumours." In Atlas of Clinical Cases on Brain Tumor Imaging, 197–248. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-23273-3_13.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Primary brain tumor"

1

Day, Emily S., Linna Zhang, Nastassja A. Lewinski, Patrick A. Thompson, Rebekah A. Drezek, Susan M. Blaney, and Jennifer L. West. "Photothermal Therapy of Glioma in a Mouse Model With Near-Infrared Excited Nanoshells." In ASME 2010 First Global Congress on NanoEngineering for Medicine and Biology. ASMEDC, 2010. http://dx.doi.org/10.1115/nemb2010-13179.

Full text
Abstract:
Glioblastoma multiforme is the most common and aggressive primary brain tumor, with median survival of approximately 10 months and only 5% of patients surviving greater than 5 years after treatment (1). Surgery and radiotherapy are the main treatment modalities for primary brain tumors, but the associated risks are high when infiltrative tumors are positioned near sensitive regions in the brain. Nanoshells, nanoparticles characterized by a spherical silica core and a gold shell, may provide the opportunity to treat brain tumors in a minimally invasive manner, reducing the risk associated with treatment. Upon exposure to a near-infrared laser, nanoshells convert light energy into heat that can thermally ablate cancerous cells (2). Targeted photothermal ablation of human glioma and medulloblastoma cells has already been demonstrated with this technique in vitro (3).
APA, Harvard, Vancouver, ISO, and other styles
2

Shetty, Anil M., Jon A. Schwartz, Joshua Yung, Roger J. McNichols, Roger Price, John D. Hazle, and R. Jason Stafford. "Gold Nanoshell Mediated Heating of Brain Tumors." In ASME 2010 First Global Congress on NanoEngineering for Medicine and Biology. ASMEDC, 2010. http://dx.doi.org/10.1115/nemb2010-13050.

Full text
Abstract:
Primary brain tumors are treated surgically or with stereotactic radiation but often residual positive margins lead to recurrence. While these approaches have success, recurrences have more limited options. These approaches also cause serious functional impairment, and treatment of a recurrent tumor in a previously irradiated or post-surgical fibrosed field is a difficult problem [1]. A controlled minimally invasive alternative is the proposed treatment of nanoshell mediated heating with intratumoral fiber placement to overcome the light penetration limitation of surface illumination.
APA, Harvard, Vancouver, ISO, and other styles
3

Jebar, Adel, Liz Ilett, Tim Kottke, Emma West, Karen Scott, Simon Thomson, Matt Coffey, et al. "Abstract A49: Systemic oncolytic reovirus for the treatment of primary and secondary brain tumors." In Abstracts: AACR Special Conference: Tumor Immunology and Immunotherapy: A New Chapter; December 1-4, 2014; Orlando, FL. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/2326-6074.tumimm14-a49.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Sundararaj, G. Kharmega, and V. Balamurugan. "Robust classification of primary brain tumor in Computer Tomography images using K-NN and linear SVM." In 2014 International Conference on Contemporary Computing and Informatics (IC3I). IEEE, 2014. http://dx.doi.org/10.1109/ic3i.2014.7019693.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

You, Min, Shu-Mei Chen, Chunjing Wu, Ying-Ying Li, Lynn Feun, Medhi Wangpaithitr, Vy Dinh, and Niramol Savaraj. "Abstract 4052: Targeting procollagen secretory pathway for the treatment of primary brain tumor through ER stress." In Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1538-7445.am2013-4052.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Zhao, Wenxue, and Jaydev P. Desai. "Towards the Development of a New Tendon-Driven Minimally Invasive Neurosurgical Intracranial Robot." In ASME 2014 Dynamic Systems and Control Conference. American Society of Mechanical Engineers, 2014. http://dx.doi.org/10.1115/dscc2014-6328.

Full text
Abstract:
Surgical resection of deep intracranial tumors under image guidance has significant challenges. The surgeon cannot see beyond the line of sight and it is also difficult to avoid the functional nerves along the path. In this context, the design of a Minimally Invasive Neurosurgical Intracranial Robot (MINIR-II) under continuous MRI is critical. The primary goal of the overall procedure is to avoid critical brain structures to reach the tumor location. Upon reaching the tumor location, the electro-cautery at the robot tip should be controlled to resect the tumor. The new MINIR-II proposed in this work, though not yet MRI compatible, is a dexterous serial chain tendon-driven robot with larger inner space, smaller outer diameter, and less coupling effect of the tendons during actuation. Each joint of the robot was attached with two tendons and they were routed outside the robot around a pulley to achieve rotational degree of freedom. The four-joint assembled robot was manufactured using a rapid prototyping machine and was tested by an experimental setup to demonstrate the motion of the robot.
APA, Harvard, Vancouver, ISO, and other styles
7

Stokol, Tracy, Mandy B. Esch, Nozomi Nishimura, Chris Schaffer, Janelle L. Daddona, David J. Post, and Dhruv P. Desai. "Little Channels, Big Disease: Using Microfluidics to Investigate Cancer Metastasis." In ASME 2011 9th International Conference on Nanochannels, Microchannels, and Minichannels. ASMEDC, 2011. http://dx.doi.org/10.1115/icnmm2011-58298.

Full text
Abstract:
The leading cause of death in human patients with malignant cancer is the dissemination of the primary tumor to secondary sites throughout the body. It is well known that cancers metastasize to certain tissues (e.g. breast cancer typically spreads to the lungs. brain and bone), in a pattern that cannot be explained by blood flow from the primary tumor or simple mechanical arrest. Circulating tumor cells usually arrest in the microvasculature of target tissues. At these sites, they must adhere to the endothelium, survive, proliferate and extravasate in order to form a secondary tumor. In vitro tools that appropriately mimic the microvasculature in which cancer metastasis occurs have been largely unavailable. With the advent of microfluidic and nanotechnology, we can now more accurately model the complexity of the microvascular environment, in terms of representative endothelial cells, geometry, shear stress and exposure to organ-specific environmental cues. This talk will focus on the use of microfluidic devices to explore mechanisms involved in tumor-endothelial cell interactions that govern cancer metastasis to organ specific sites.
APA, Harvard, Vancouver, ISO, and other styles
8

Pappafotis, Nicholas, Wojciech Bejgerowski, Rao Gullapalli, J. Marc Simard, Satyandra K. Gupta, and Jaydev P. Desai. "Towards Design and Fabrication of a Miniature MRI-Compatible Robot for Applications in Neurosurgery." In ASME 2008 International Design Engineering Technical Conferences and Computers and Information in Engineering Conference. ASMEDC, 2008. http://dx.doi.org/10.1115/detc2008-49587.

Full text
Abstract:
Brain tumors are among the most feared complications of cancer and they occur in 20–40% of adult cancer patients. Despite numerous advances in treatment, the prognosis for these patients is poor, with a median survival of 4–8 months. The primary reasons for poor survival rate are the lack of good continuous imaging modality for intraoperative intracranial procedures and the inability to remove the complete tumor tissue due to its placement in the brain and the corresponding space constraints to reach it. Intraoperative magnetic resonance imaging (MRI) supplements the surgeon’s visual and tactile senses in a way that no other imaging device can achieve resulting in less trauma to surrounding healthy brain tissue during surgery. To minimize the trauma to surrounding healthy brain tissue, it would be beneficial to operate through a narrow surgical corridor dissected by the neurosurgeon. Facilitating tumor removal by accessing regions outside the direct “line-of-sight” of the neurosurgical corridor will require a highly dexterous, small cross section, and MRI-compatible robot. Developing such a robot is extremely challenging task. In this paper we report a preliminary design of 6-DOF robot for possible application in neurosurgery. The robot actuators and body parts are constructed from MRI compatible materials. The current prototype is 0.36” in diameter and weighs only 0.0289 N (2.95 grams). The device was actuated using Flexinol® which is a shape memory alloy manufactured by Dynalloy, Inc. The end-effector forces ranged from 12 mN to 50 mN depending on the robot configuration. The end-effector force to robot weight ratio varied from 0.41 to 1.73. During trials the robot motion was repeatable and the range of motion of the robot was about 90 degrees for the end-effector when one side shape memory alloy (SMA) channel was actuated. The actuation time from the start to finish was about 2.5 s.
APA, Harvard, Vancouver, ISO, and other styles
9

Ajikumar, S., and A. Jayachandran. "Early diagnosis of primary tumor in brain MRI images using wavelet as the input of Ada-Boost classifier." In 2014 International Conference on Contemporary Computing and Informatics (IC3I). IEEE, 2014. http://dx.doi.org/10.1109/ic3i.2014.7019699.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Ho, Mingyen, and Jaydev P. Desai. "Towards the Development of a Tendon-Driven Neurosurgical Robot." In ASME 2011 Dynamic Systems and Control Conference and Bath/ASME Symposium on Fluid Power and Motion Control. ASMEDC, 2011. http://dx.doi.org/10.1115/dscc2011-6075.

Full text
Abstract:
Brain tumors are among the most feared complications of cancer and their treatment is challenging due to the lack of good continuous imaging modality during the procedure and the inability to remove the complete tumor due to obstructions. A highly dexterous, small cross-section robot is being developed to overcome these limitations. The robot is being designed to remove the tumor which is outside the direct “line-of-sight” of the physician. In this paper, we report the design of a Minimally Invasive Neurosurgical Intracranial Robot (MINIR) using a tendon-driven mechanism. In the current prototype presented in this paper, the actuators for actuating the robot are not MRI compatible. The primary goal of this paper is to evaluate the performance of the robot motion and not the MRI compatibility of the entire system. The robot contains four links and four revolute joints. Pulleys and cables are put inside the robot to make the robot compact. The four revolute joints are placed orthogonally to have out-of-plane motion capability and can be controlled independently.
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Primary brain tumor' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography